Thursday, 15 October 2026European Markets

FRANCAISE ENERGIE Stock Jumps By 21% In The Last 10 Sessions

Loading stream...

(vianews) - shares of francaise energie (cac 40: fde.pa) rose by a staggering 21.57% in 10 sessions from €35 to €42.55 at 20:53 est on thursday, following the last session's downward trend. cac 40 is dropping 0.33% to €7,229.27, after three successive sessions in a row of losses.

about francaise energie

la française de l'energie s.a., a carbon-negative energy producer, focuses on energy recovery and production sites for reducing greenhouse gas emissions in france. the company supplies co2, gas, electricity, and heat. it has an installed capacity of 7.5 megawatts in wallonia. la française de l'energie s.a. was incorporated in 2007 and is headquartered in faulquemont, france.

earnings per share

as for profitability, francaise energie has a trailing twelve months eps of €2.9.

pe ratio

francaise energie has a trailing twelve months price to earnings ratio of 14.67. meaning, the purchaser of the share is investing €14.67 for every euro of annual earnings.

volume

today's last reported volume for francaise energie is 6566 which is 68.81% below its average volume of 13470.

more news about francaise energie (fde.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com